Methods and Materials Relating to CD84-like Polypeptides and Polynucleotides

Abstract

The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human spleen (Hyseq clone identification numbers 2938352 (SEQ ID NO: 1)). Other aspects of the invention include vectors containing processes for producing novel human secreted CD84-like polypeptides, and antibodies specific for such polypeptides.

1 . An isolated antibody that binds with high affinity to a polypeptide comprising an amino acid sequence with at least 95% sequence identity to the amino acid sequence comprising SEQ ID NO: 4, or the mature protein portion thereof. 
     
     
         2 . The antibody of  claim 1 , wherein said antibody binds with high affinity to a polypeptide comprising an amino acid sequence with at least 99% identity to the amino acid sequence comprising SEQ ID NO: 4, or the mature protein portion thereof. 
     
     
         3 . The antibody of  claim 1 , wherein said antibody binds with high affinity to a polypeptide comprising the amino acid sequence of SEQ ID NO: 4, or the mature protein portion thereof. 
     
     
         4 . The antibody of  claim 1 , wherein the antibody is a polyclonal antibody or antibody fragment thereof. 
     
     
         5 . The antibody of  claim 1 , wherein the antibody is a monoclonal antibody or antibody fragment thereof. 
     
     
         6 . The antibody of  claim 1 , wherein the antibody is a chimeric antibody or antibody fragment thereof. 
     
     
         7 . The antibody of  claim 1 , wherein the antibody is a human or humanized antibody or antibody fragment thereof. 
     
     
         8 . A composition comprising the antibody of  claim 1  and a carrier. 
     
     
         9 . A method of treating cancer in a subject in need thereof, said method comprising administering to said subject a composition comprising a therapeutically effective amount of the antibody of  claim 1 . 
     
     
         10 . The method of  claim 9 , wherein the cancer is a blood cell malignancy. 
     
     
         11 . The method of  claim 10 , wherein the blood cell malignancy is selected from the group consisting of leukemia and lymphoma. 
     
     
         12 . The method of  claim 10 , wherein the blood cell malignancy is chronic lymphocytic leukemia. 
     
     
         13 . The method of  claim 9 , wherein the subject is a mammal. 
     
     
         14 . The method of  claim 9 , wherein the subject is a human.